Compare DuPont de Nemours Inc (DD) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DuPont de Nemours Inc vs Recursion Pharmaceuticals Inc — how do they compare? DuPont de Nemours Inc trades at $131.75 (market cap $17.89B), while Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.14B). The key difference: DuPont de Nemours Inc is far larger — about 8.4× Recursion Pharmaceuticals Inc's market cap, and DuPont de Nemours Inc pays a 1.81% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold DuPont de Nemours Inc for 89 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| DD | RXRX | |
|---|---|---|
Market Cap | $17.89B | $2.14B |
Volume | 816,409 | 30,789,535 |
Sector | Basic Materials | Health |
52-Week High | $154.59 | $6.79 |
52-Week Low | $92.49 | $2.84 |
Typical Hold Time | 89 Days | 22 Days |
Enterprise Value | $19.28B | $1.66B |
Dividend Yield | 1.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DuPont (DD) trades at $131.08, down 1.65% on the day, with neutral technical signals from moving averages and oscillators. The company shows mixed fundamentals with recent earnings beats but declining revenue from $12.4B in 2024 to $6.85B in 2025, resulting in a net loss of $779M. Analyst sentiment remains positive with 58.5% buy ratings, though the consensus price target of $95 suggests caution. Recent developments include new product launches in sugar separation technology and Tyvek innovations, alongside ongoing PFAS litigation settlements.
The outlook for DD hinges on margin recovery and growth in key sectors like healthcare and water technologies, but investors face risks from legal liabilities, volatile cash flows, and high P/E valuation. Institutional activity shows mixed signals with both position reductions and significant increases, reflecting uncertainty about near-term performance amid structural growth opportunities.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
